SGLT2 inhibitors as metabolic senolytics: clearing senescent cells to combat pathological aging

For nearly a decade, SGLT2 inhibitors such as empagliflozin, dapagliflozin, bexagliflozin, and the newer henagliflozin have been reshaping the treatment of type 2 diabetes. These medications were originally designed to lower blood glucose by helping the kidneys remove excess sugar from the blood in urine. Soon after their introduction, it became clear that their impact reached far beyond glucose control. Clinical trials consistently showed benefits across three major systems: metabolic regulation, cardiovascular protection, and kidney health, all within a safety profile that has made them widely used and well-trusted.

Inside the first human trial testing an SGLT2 inhibitor on biological aging

For nearly a decade, SGLT2 inhibitors such as empagliflozin, dapagliflozin, bexagliflozin, and the newer henagliflozin have been reshaping the treatment of type 2 diabetes. These medications were originally designed to lower blood glucose by helping the kidneys remove excess sugar from the blood in urine. Soon after their introduction, it became clear that their impact reached far beyond glucose control. Clinical trials consistently showed benefits across three major systems: metabolic regulation, cardiovascular protection, and kidney health, all within a safety profile that has made them widely used and well-trusted.

The same features that make these drugs effective in metabolic disease have drawn growing attention from researchers studying human longevity. SGLT2 inhibitors reduce the body’s reliance on glucose, shift cells toward burning fats, support more efficient mitochondrial energy production, and lower chronic inflammation. Many of these are the same physiological changes observed during caloric restriction, an intervention known to extend lifespan in several species. Because of this overlap, SGLT2 inhibitors are now being investigated as potential “caloric-restriction mimetics,” capable of producing fasting-like cellular benefits without major dietary changes.

What they found: telomere outcomes

For nearly a decade, SGLT2 inhibitors such as empagliflozin, dapagliflozin, bexagliflozin, and the newer henagliflozin have been reshaping the treatment of type 2 diabetes. These medications were originally designed to lower blood glucose by helping the kidneys remove excess sugar from the blood in urine. Soon after their introduction, it became clear that their impact reached far beyond glucose control. Clinical trials consistently showed benefits across three major systems: metabolic regulation, cardiovascular protection, and kidney health, all within a safety profile that has made them widely used and well-trusted.

The same features that make these drugs effective in metabolic disease have drawn growing attention from researchers studying human longevity. SGLT2 inhibitors reduce the body’s reliance on glucose, shift cells toward burning fats, support more efficient mitochondrial energy production, and lower chronic inflammation. Many of these are the same physiological changes observed during caloric restriction, an intervention known to extend lifespan in several species. Because of this overlap, SGLT2 inhibitors are now being investigated as potential “caloric-restriction mimetics,” capable of producing fasting-like cellular benefits without major dietary changes.

Why IGFBP-3 matters for longevity biology

For nearly a decade, SGLT2 inhibitors such as empagliflozin, dapagliflozin, bexagliflozin, and the newer henagliflozin have been reshaping the treatment of type 2 diabetes. These medications were originally designed to lower blood glucose by helping the kidneys remove excess sugar from the blood in urine. Soon after their introduction, it became clear that their impact reached far beyond glucose control. Clinical trials consistently showed benefits across three major systems: metabolic regulation, cardiovascular protection, and kidney health, all within a safety profile that has made them widely used and well-trusted.

The same features that make these drugs effective in metabolic disease have drawn growing attention from researchers studying human longevity. SGLT2 inhibitors reduce the body’s reliance on glucose, shift cells toward burning fats, support more efficient mitochondrial energy production, and lower chronic inflammation. Many of these are the same physiological changes observed during caloric restriction, an intervention known to extend lifespan in several species. Because of this overlap, SGLT2 inhibitors are now being investigated as potential “caloric-restriction mimetics,” capable of producing fasting-like cellular benefits without major dietary changes.